GHAPPcast

Med Review: SEQUENCE Trial: Risankizumab vs Ustekinumab in Anti-TNF-Refractory Crohn’s Disease

Thank you to AbbVie for their support on this Medication Review Video Module. In this medication review, Sharon Dudley-Brown, CRNP, PhD from Johns Hopkins University and Angelina Collins, MSN, ANP-BC, from the University of California San Diego, provide a comprehensive overview of the SEQUENCE trial, a landmark head-to-head study comparing risankizumab and ustekinumab in patients with moderate to severe Crohn’s disease who had previously failed anti-TNF therapy. The discussion explores the trial design, patient population, dosing strategies, primary and secondary endpoints, and the significance of efficacy assessor blinding in an open-label study. Sharon and Angelina review key findings demonstrating the superiority of risankizumab over ustekinumab across multiple clinical and endoscopic outcomes, including clinical remission, endoscopic response, corticosteroid-free remission, and long-term disease control. They also discuss the importance of objective disease assessment using centrally read endoscopy and the role of steroid tapering in evaluating treatment success. Safety outcomes are examined, highlighting the absence of new safety signals and reinforcing the established safety profile of risankizumab. This educational video is designed for gastroenterology nurse practitioners, physician assistants, and other healthcare professionals seeking practical insights into evidence-based treatment selection for Crohn’s disease. Viewers will gain a deeper understanding of how the SEQUENCE study may influence treatment positioning of IL-23 therapies in anti-TNF-experienced patients and how emerging long-term extension data continue to support durable clinical remission and endoscopic improvement with risankizumab.

FAQ: QUASAR Long Term Extension Interim Analysis

Thank you to Johnson & Johnson for their support on this FAQ Video Module. In this educational video, Jamie Brogan, APRN, from Northwestern Medicine, reviews the latest QUASAR long-term extension data evaluating the efficacy and safety of guselkumab in adults with moderate to severe ulcerative colitis. This discussion highlights approximately two years of follow-up data, offering healthcare providers valuable insight into the long-term durability of treatment response, clinical remission, endoscopic improvement, and overall safety outcomes associated with guselkumab maintenance therapy. Jamie walks through the key findings from the ongoing multicenter extension study, including sustained clinical remission rates, corticosteroid-free remission, endoscopic healing, and histologic-endoscopic mucosal improvement through week 92. The video also reviews the maintenance dosing strategies of guselkumab, including 100 mg every 8 weeks and 200 mg every 4 weeks, and discusses how patients who responded during earlier phases of treatment maintained those responses over time. In addition, the presentation covers important long-term safety findings, including rates of serious infections and adverse events observed throughout the study. This video is designed for gastroenterology APPs, nurse practitioners, physician assistants, gastroenterologists, and healthcare professionals looking to stay current on emerging ulcerative colitis therapies, long-term biologic data, and evolving treatment goals in inflammatory bowel disease (IBD). For more educational content on ulcerative colitis, Crohn’s disease, gastroenterology, and hepatology, visit the GHAPP Digital Hub and the GHAPP ACE app.

Medication Review: Guselkumab IV vs SC Formulation

Thank you to Johnson & Johnson for their support on this Medication Review Video Module. In this quick educational video, Angelina Collins, NP, from the University of California San Diego Inflammatory Bowel Disease Center, discusses an important question in Crohn’s disease treatment. This overview breaks down the key findings from the GALAXI and GRAVITI clinical trials in a clear, practical way, helping healthcare providers better understand the effectiveness and safety of both treatment approaches for patients with moderate to severe Crohn’s disease. Angelina explains the differences between IV and subcutaneous induction dosing, maintenance treatment options, and how these choices can support shared decision-making between providers and patients. Whether patients are new to advanced therapies or have previous biologic experience, this discussion highlights how both induction options may provide strong results without compromising safety. This video is designed for gastroenterology APPs, nurse practitioners, physician assistants, gastroenterologists, and healthcare professionals looking for practical insights into Crohn’s disease management and evolving IBD treatment strategies. For more GI and hepatology education, visit the GHAPP Digital Hub and the GHAPP ACE app.

FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease

Thank you to Salix for the support on this FAQ Video Module. This educational FAQ module, featuring Mikhail Alper, PA-C focuses on recognizing risk factors and early clinical indicators of Overt Hepatic Encephalopathy (OHE) in patients with chronic liver disease and cirrhosis. A central focus is placed on subtle and often underrecognized manifestations of OHE risk, including disrupted sleep, wake cycles, daytime somnolence, intermittent confusion, and short-term memory lapses. These early signs may be easily missed without targeted questioning and careful clinical evaluation, particularly in younger or ambulatory patients with cirrhosis. Learn how proactive screening and early recognition of cognitive and behavioral changes can support timely identification of OHE risk in chronic liver disease. The review highlights the importance of clinician awareness in preventing progression to more severe neurocognitive impairment and supporting earlier intervention strategies in at risk patients. For more educational content visit the GHAPP Digital Hub or the GHAPP ACE app.

FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease

Thank you to Johnson & Johnson for the support on this FAQ Video Module. This FAQ video features Janette Villalon, PA, who reviews the role of guselkumab in treating extraintestinal manifestations in patients with moderately to severely active Crohn’s disease. In this expert-led discussion, she summarizes findings from the GALAXI 2 and GALAXI 3 clinical trials presented at a 2026 medical congress, which used a treat-through study design intended to reflect real-world clinical practice. The focus of the analysis is on how patients with Crohn’s disease respond over time when treated with guselkumab compared to placebo. The data presented focuses on key outcomes such as improvement and resolution of extraintestinal manifestations, including joint and skin symptoms, along with measures like steroid-free remission and the emergence of new symptoms over time. At baseline, a notable proportion of patients in both the guselkumab and placebo groups had extraintestinal involvement, most commonly arthralgia, with skin manifestations occurring less frequently. This educational FAQ highlights how clinicians are evaluating guselkumab as part of a broader strategy for managing Crohn’s disease, with attention to both symptom control and durability of response over time. It provides practical insights for gastroenterology advanced practice providers and healthcare professionals as they balance effectiveness, long-term disease control, and comprehensive care of patients with inflammatory bowel disease in clinical practice. Visit the GHAPP Website, GHAPP Digital Hub or GHAPP ACE app for additional educational content.